Harmony Biosciences Holdings, Inc. HRMY

HRMY Company Overview

Harmony Biosciences Holdings, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological and sleep-related disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with an emphasis on orphan and underserved indications. Its core business centers on identifying clinically differentiated assets, advancing them through targeted development, and commercializing them primarily in the United States.

Harmony’s primary revenue driver is WAKIX® (pitolisant), a first-in-class histamine 3 (H3) receptor antagonist/inverse agonist approved in the U.S. for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company serves a specialized physician and patient population within sleep medicine and neurology. Strategically, Harmony differentiates itself through a focused commercial model in rare diseases, long product lifecycle management, and licensing arrangements that allow it to leverage established science while controlling U.S. commercialization. Founded in 2017, Harmony completed its initial public offering in 2020 and has since evolved into a profitable, commercial-stage biopharmaceutical company.